Literature DB >> 7209880

Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.

K Kobayashi, K Maeda, S Koshikawa, Y Kawaguchi, N Shimizu, C Naito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7209880     DOI： 10.1016/0049-3848(80)90390-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  11 in total

Review 1.  Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.

Authors:  M Verstraete
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 3.  Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.

Authors:  D McTavish; D Faulds; K L Goa
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

5.  Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

Authors:  Charmaine E Lok; Louise Moist; Brenda R Hemmelgarn; Marcello Tonelli; Miguel A Vazquez; Marc Dorval; Matthew Oliver; Sandra Donnelly; Michael Allon; Kenneth Stanley
Journal:  JAMA       Date:  2012-05-02       Impact factor: 56.272

Review 6.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 8.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

Review 9.  Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates.

Authors:  Swapnil Hiremath; Rachel M Holden; Dean Fergusson; Deborah L Zimmerman
Journal:  Clin J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 8.237

Review 10.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.